• Deutsch
Login

Open Access

  • Home
  • Search
  • Browse
  • Publish/report a document
  • Help

Refine

Author

  • Bailey, Nathanael G. (1)
  • Basrur, Venkatesha (1)
  • Chen, Xiaofei (1)
  • Chhipa, Rishi R. (1)
  • Conlon, Kevin P. (1)
  • Dreval, Kostiantyn (1)
  • Elenitoba-Johnson, Kojo S. J. (1)
  • Hogaboam, Cory M. (1)
  • Kapoor, Richa (1)
  • Kim, Junhyong (1)
+ more

Institute

  • Fakultät für Angewandte Informatik (1)
  • Institut für Informatik (1)
  • Lehrstuhl für Biomedizinische Informatik, Data Mining und Data Analytics (1)

1 search hit

  • 1 to 1
  • 10
  • 20
  • 50
  • 100
The FBXO45-GEF-H1 axis controls germinal center formation and B-cell lymphomagenesis (2025)
Sahasrabuddhe, Anagh A. ; Chen, Xiaofei ; Ma, Kaiyu ; Wu, Rui ; Liang, Huan-Chang ; Kapoor, Richa ; Chhipa, Rishi R. ; Onder, Ozlem ; McFetridge, Courtney ; Van Arnam, John S. ; Zhang, Xiao ; Morrissette, Jennifer J. D. ; Pillai, Vinodh ; Li, Marilyn M. ; Szankasi, Philippe ; Basrur, Venkatesha ; Conlon, Kevin P. ; Raabe, Tobias D. ; Bailey, Nathanael G. ; Hogaboam, Cory M. ; Rottapel, Robert ; Kim, Junhyong ; López, Cristina ; Schlesner, Matthias ; Siebert, Reiner ; Dreval, Kostiantyn ; Morin, Ryan D. ; Moro, Loredana ; Pagano, Michele ; Staudt, Louis M. ; Lim, Megan S. ; Elenitoba-Johnson, Kojo S. J.
The role of ubiquitin-mediated degradation mechanisms in the pathogenesis of diffuse large B-cell lymphoma (BCL) and follicular lymphoma is not completely understood. We show that conditional deletion of the E3 ubiquitin ligase Fbxo45 in germinal center B cells results in B-cell lymphomagenesis in homozygous (100%) and heterozygous (48%) mice. Mechanistically, FBXO45 targets the RHO guanine exchange factor ARHGEF2/GEF-H1 for ubiquitin-mediated degradation. Double genetic ablation of Fbxo45 and Arhgef2 ameliorated lymphoma formation. Transgenic knock-in mice harboring a GEF-H1 mutant unable to bind FBXO45 develop BCLs with ∼50% penetrance. Genome sequencing in human lymphomas identified mutually exclusive FBXO45 copy-number losses and ARHGEF2 gains, with combined frequencies ranging from 26.32% in follicular lymphoma to 45.12% in diffuse large BCL. Notably, FBXO45 silencing enhances sensitivity to MEK1/2 inhibition. These results identify FBXO45 and ARHGEF2 as a novel tumor suppressor and oncogene pair involved in the pathogenesis of BCLs with important implications for targeted therapies.
  • 1 to 1

OPUS4 Logo

  • Contact
  • Imprint
  • Sitelinks